Manufacturer of Controlled Substances; Notice of Application; GE Healthcare, 12103 [2013-03895]
Download as PDF
<![CDATA[
12103
Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices
Drug
Schedule
erowe on DSK2VPTVN1PROD with NOTICES
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5dimethoxyamphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4methylenedioxyamphetamine
(7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4Methylenedioxymethamphetamine (MDMA) (7405).
Psilocybin (7437) ..........................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
1-[1-(2Thienyl)cyclohexyl]piperidine
(TCP) (7470).
N-Benzylpiperazine (BZP) (7493)
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Nabilone (7379) ............................
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Remifentanil (9739) ......................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
I
I
I
I
I
14:47 Feb 20, 2013
BILLING CODE 4410–09–P
I
DEPARTMENT OF JUSTICE
I
Drug Enforcement Administration
I
Manufacturer of Controlled
Substances; Notice of Application; GE
Healthcare
I
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 31, 2012,
GE Healthcare, 3350 North Ridge
Avenue, Arlington Heights, Illinois
60004–1412, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance
listed in schedule II.
The company plans to manufacture a
radioactive product to diagnose
Parkinson’s disease; and to manufacture
a bulk investigational new drug (IND)
for clinical trials.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such a substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Jkt 229001
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
[FR Doc. 2013–03893 Filed 2–20–13; 8:45 am]
The company plans to manufacture
reference standards.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
VerDate Mar<15>2010
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03895 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances, Notice of Application;
Alltech Associates, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 19,
2012, Alltech Associates Inc., 2051
Waukegan Road, Deerfield, Illinois
60015, made application to the Drug
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
5-Methoxy-N–Ndimethyltryptamine (7431).
2C–E
(2-(2,5-Dimethoxy-4ethylphenyl)ethanamine) (7509).
2C–H
(2-(2,5Dimethoxyphenyl)ethanamine)
(7517).
2C–T–4 (2-(4-isopropylthio)-2,5dimethoxyphenyl) ethanamine)
(7532).
Schedule
I
I
I
I
The company plans to manufacture
high purity drug standards used for
analytical applications only in clinical,
toxicological, and forensic laboratories.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–03919 Filed 2–20–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Cody Laboratories, Inc.
By Notice dated November 1, 2012,
and published in the Federal Register
on November 9, 2012, 77 FR 67398,
Cody Laboratories, Inc., ATTN: Richard
Asherman, 601 Yellowstone Avenue,
Cody, Wyoming 82414, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Dihydromorphine (9145) ................
Amphetamine (1100) ......................
Methamphetamine (1105) ..............
E:\FR\FM\21FEN1.SGM
21FEN1
Schedule
I
II
II
]]>Agencies
[Federal Register Volume 78, Number 35 (Thursday, February 21, 2013)]
[Notices]
[Page 12103]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-03895]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application; GE
Healthcare
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on August 31, 2012, GE
Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004-
1412, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of Cocaine
(9041), a basic class of controlled substance listed in schedule II.
The company plans to manufacture a radioactive product to diagnose
Parkinson's disease; and to manufacture a bulk investigational new drug
(IND) for clinical trials.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such a substance, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than April 22, 2013.
Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-03895 Filed 2-20-13; 8:45 am]
BILLING CODE 4410-09-P
